Literature DB >> 28895205

Baseline low serum dehydroepiandrosterone sulfate can predict poor responsiveness to hormone therapy in patients with hormone-naïve prostate cancer with skeletal metastases.

Akihiro Yano1, Makoto Kagawa1, Hideki Takeshita1, Yohei Okada1, Makoto Morozumi1, Satoru Kawakami1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28895205     DOI： 10.1111/iju.13445

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


× No keyword cloud information.
  2 in total

1.  Initial 3-month dynamics of dehydroepiandrosterone sulfate can predict responsiveness to primary androgen deprivation therapy in patients with metastatic prostate cancer.

Authors:  Akihiro Yano; Makoto Kagawa; Hideki Takeshita; Yohei Okada; Makoto Morozumi; Satoru Kawakami
Journal:  Asian J Androl       Date:  2019 Nov-Dec       Impact factor: 3.285

2.  Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival.

Authors:  Jessica Whitburn; Srinivasa R Rao; Emma V Morris; Sho Tabata; Akiyoshi Hirayama; Tomoyoshi Soga; James R Edwards; Zeynep Kaya; Charlotte Palmer; Freddie C Hamdy; Claire M Edwards
Journal:  Sci Adv       Date:  2022-02-25       Impact factor: 14.136
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.